Finasteride Market By Application (Benign Prostatic Hyperplasia (BPH), Male pattern baldness), By Type (Branded , Generic), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031
The finasteride market valued for $362.11 million in 2021 and is estimated to reach $546.72 million by 2031, exhibiting a CAGR of 4.2% from 2022 to 2031.
Finasteride is a medication used primarily for the treatment of male pattern baldness and benign prostatic hyperplasia (BPH). It works by blocking the conversion of testosterone to dihydrotestosterone (DHT), a hormone that contributes to hair loss and prostate enlargement. The major factors driving the growth of the finasteride market include rise in prevalence of hair loss and benign prostatic hyperplasia (BPH), as well as surge in awareness about the benefits of finasteride treatment. For instance, article published in National Library of Medicine 2021, stated that, male pattern baldness affects up to 2% of general population. This rise in male pattern baldness is anticipated to drive the growth of the market.
In addition, a rise in prevalence of benign prostatic hyperplasia (BPH) is expected to fuel the market growth. For instance, according to an article published in Lancet Healthy Longevity Journal 2022, a total of 94 million prevalent cases of benign prostatic hyperplasia (BPH) were reported in 2019 across the globe. Further, as the global population continues to age, there is a witnessed increase in the incidence of benign prostatic hyperplasia (BPH) and other prostate-related conditions. This has led to a rise in demand for medications such as finasteride, which help manage benign prostatic hyperplasia (BPH) symptoms. Thus, a rise in geriatric population is anticipated to drive the growth of the market.
Further, the availability of generic types of finasteride has contributed to the growth of the market, as it has made the medication affordable and accessible to a wider population. For instance, Dr. Reddy’s Laboratories Ltd., offers finasteride tablets in generic type, thus, such availability of generic type of finasteride is expected to propel market expansion. Moreover, a rise in the number of key players offering finasteride in branded and generic form is expected to fuel the growth of the market. For instance, key players such as Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd., offer finasteride in branded and generic versions such as PROSCAR (Finasteride). Thus, the presence of such key players offering finasteride fuels the growth of the market.
Furthermore, rise in disposable income also drives the market growth owing to increased demand for medications that improve physical appearance, such as finasteride for male pattern hair loss. In addition, individuals may be willing to invest in treatments that can help them look and feel better, with an increase in disposable income.
However, alternative treatments for male pattern baldness and benign prostatic hyperplasia (BPH), such as hair transplant surgery and availability of other alternate medications are the factors which restrain the growth of the finasteride market. In addition, the absence of favorable reimbursement policies is also expected to constrain the growth of the market. Further, rise in demand for finasteride and increase in awareness about finasteride for male pattern baldness offers lucrative opportunities to key players of the finasteride market.
The finasteride market is segmented into application, type, distribution channel and region. On the basis of application, the market is bifurcated into benign prostatic hyperplasia (BPH), and male pattern baldness. On the basis of type, the market is categorized into branded and generic. On the basis of distribution channel, the market is segregated into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global finasteride market include Alkem Laboratories Ltd, Dr. Reddy’s Laboratories Ltd., HETERO LABS LIMITED, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Organon & Co., Cipla Ltd., and Aurobindo Pharma.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the finasteride market analysis from 2021 to 2031 to identify the prevailing finasteride market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the finasteride market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global finasteride market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Application
Benign Prostatic Hyperplasia (BPH)
Male pattern baldness
By Type
Branded
Generic
By Distribution Channel
Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Alkem Laboratories Ltd
HETERO LABS LIMITED
Merck & Co., Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Intas Pharmaceuticals Ltd.
Organon & Co.
Aurobindo Pharma
Cipla Ltd
Dr. Reddy’s Laboratories Ltd.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rise in prevalence of male pattern baldness
- 3.4.1.2. Rise in adoption of finasteride for benign prostatic hyperplasia (BPH)
- 3.4.1.3. Increase in adherence of finasteride for treatment of BPH and male pattern baldness
- 3.4.2. Restraints
- 3.4.2.1. Side effects associated with finasteride
- 3.4.2.2. Competition from other medications and availability of alternate medicine
- 3.4.3. Opportunities
- 3.4.3.1. Growth opportunities in emerging markets
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: FINASTERIDE MARKET, BY APPLICATION
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Benign Prostatic Hyperplasia (BPH)
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Male pattern baldness
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- CHAPTER 5: FINASTERIDE MARKET, BY TYPE
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Branded
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Generic
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- CHAPTER 6: FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Online Providers
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Drug Stores and Retail Pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: FINASTERIDE MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Application
- 7.2.3. Market size and forecast, by Type
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Key market trends, growth factors and opportunities
- 7.2.5.1.2. Market size and forecast, by Application
- 7.2.5.1.3. Market size and forecast, by Type
- 7.2.5.1.4. Market size and forecast, by Distribution Channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Key market trends, growth factors and opportunities
- 7.2.5.2.2. Market size and forecast, by Application
- 7.2.5.2.3. Market size and forecast, by Type
- 7.2.5.2.4. Market size and forecast, by Distribution Channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Key market trends, growth factors and opportunities
- 7.2.5.3.2. Market size and forecast, by Application
- 7.2.5.3.3. Market size and forecast, by Type
- 7.2.5.3.4. Market size and forecast, by Distribution Channel
- 7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Application
- 7.3.3. Market size and forecast, by Type
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Key market trends, growth factors and opportunities
- 7.3.5.1.2. Market size and forecast, by Application
- 7.3.5.1.3. Market size and forecast, by Type
- 7.3.5.1.4. Market size and forecast, by Distribution Channel
- 7.3.5.2. France
- 7.3.5.2.1. Key market trends, growth factors and opportunities
- 7.3.5.2.2. Market size and forecast, by Application
- 7.3.5.2.3. Market size and forecast, by Type
- 7.3.5.2.4. Market size and forecast, by Distribution Channel
- 7.3.5.3. UK
- 7.3.5.3.1. Key market trends, growth factors and opportunities
- 7.3.5.3.2. Market size and forecast, by Application
- 7.3.5.3.3. Market size and forecast, by Type
- 7.3.5.3.4. Market size and forecast, by Distribution Channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Key market trends, growth factors and opportunities
- 7.3.5.4.2. Market size and forecast, by Application
- 7.3.5.4.3. Market size and forecast, by Type
- 7.3.5.4.4. Market size and forecast, by Distribution Channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Key market trends, growth factors and opportunities
- 7.3.5.5.2. Market size and forecast, by Application
- 7.3.5.5.3. Market size and forecast, by Type
- 7.3.5.5.4. Market size and forecast, by Distribution Channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Key market trends, growth factors and opportunities
- 7.3.5.6.2. Market size and forecast, by Application
- 7.3.5.6.3. Market size and forecast, by Type
- 7.3.5.6.4. Market size and forecast, by Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Application
- 7.4.3. Market size and forecast, by Type
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Key market trends, growth factors and opportunities
- 7.4.5.1.2. Market size and forecast, by Application
- 7.4.5.1.3. Market size and forecast, by Type
- 7.4.5.1.4. Market size and forecast, by Distribution Channel
- 7.4.5.2. China
- 7.4.5.2.1. Key market trends, growth factors and opportunities
- 7.4.5.2.2. Market size and forecast, by Application
- 7.4.5.2.3. Market size and forecast, by Type
- 7.4.5.2.4. Market size and forecast, by Distribution Channel
- 7.4.5.3. Australia
- 7.4.5.3.1. Key market trends, growth factors and opportunities
- 7.4.5.3.2. Market size and forecast, by Application
- 7.4.5.3.3. Market size and forecast, by Type
- 7.4.5.3.4. Market size and forecast, by Distribution Channel
- 7.4.5.4. India
- 7.4.5.4.1. Key market trends, growth factors and opportunities
- 7.4.5.4.2. Market size and forecast, by Application
- 7.4.5.4.3. Market size and forecast, by Type
- 7.4.5.4.4. Market size and forecast, by Distribution Channel
- 7.4.5.5. South Korea
- 7.4.5.5.1. Key market trends, growth factors and opportunities
- 7.4.5.5.2. Market size and forecast, by Application
- 7.4.5.5.3. Market size and forecast, by Type
- 7.4.5.5.4. Market size and forecast, by Distribution Channel
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Key market trends, growth factors and opportunities
- 7.4.5.6.2. Market size and forecast, by Application
- 7.4.5.6.3. Market size and forecast, by Type
- 7.4.5.6.4. Market size and forecast, by Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Application
- 7.5.3. Market size and forecast, by Type
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Key market trends, growth factors and opportunities
- 7.5.5.1.2. Market size and forecast, by Application
- 7.5.5.1.3. Market size and forecast, by Type
- 7.5.5.1.4. Market size and forecast, by Distribution Channel
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Key market trends, growth factors and opportunities
- 7.5.5.2.2. Market size and forecast, by Application
- 7.5.5.2.3. Market size and forecast, by Type
- 7.5.5.2.4. Market size and forecast, by Distribution Channel
- 7.5.5.3. South Africa
- 7.5.5.3.1. Key market trends, growth factors and opportunities
- 7.5.5.3.2. Market size and forecast, by Application
- 7.5.5.3.3. Market size and forecast, by Type
- 7.5.5.3.4. Market size and forecast, by Distribution Channel
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Key market trends, growth factors and opportunities
- 7.5.5.4.2. Market size and forecast, by Application
- 7.5.5.4.3. Market size and forecast, by Type
- 7.5.5.4.4. Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2021
- CHAPTER 9: COMPANY PROFILES
- 9.1. Alkem Laboratories Ltd
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.2. Dr. Reddy’s Laboratories Ltd.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.3. HETERO LABS LIMITED
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.4. Intas Pharmaceuticals Ltd.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.5. Merck & Co., Inc.
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.6. Organon & Co.
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.7. Sun Pharmaceutical Industries Ltd.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.8. Teva Pharmaceutical Industries Ltd.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.9. Cipla Ltd
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.10. Aurobindo Pharma
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- LIST OF TABLES
- TABLE 01. GLOBAL FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 02. FINASTERIDE MARKET FOR BENIGN PROSTATIC HYPERPLASIA (BPH), BY REGION, 2021-2031 ($MILLION)
- TABLE 03. FINASTERIDE MARKET FOR MALE PATTERN BALDNESS, BY REGION, 2021-2031 ($MILLION)
- TABLE 04. GLOBAL FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 05. FINASTERIDE MARKET FOR BRANDED , BY REGION, 2021-2031 ($MILLION)
- TABLE 06. FINASTERIDE MARKET FOR GENERIC, BY REGION, 2021-2031 ($MILLION)
- TABLE 07. GLOBAL FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 08. FINASTERIDE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 09. FINASTERIDE MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. FINASTERIDE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. FINASTERIDE MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. NORTH AMERICA FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 13. NORTH AMERICA FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 14. NORTH AMERICA FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 15. NORTH AMERICA FINASTERIDE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 16. U.S. FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 17. U.S. FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 18. U.S. FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 19. CANADA FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 20. CANADA FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 21. CANADA FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 22. MEXICO FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 23. MEXICO FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 24. MEXICO FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 25. EUROPE FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 26. EUROPE FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 27. EUROPE FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 28. EUROPE FINASTERIDE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 29. GERMANY FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 30. GERMANY FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 31. GERMANY FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 32. FRANCE FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 33. FRANCE FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 34. FRANCE FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 35. UK FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 36. UK FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 37. UK FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 38. ITALY FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 39. ITALY FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 40. ITALY FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 41. SPAIN FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 42. SPAIN FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 43. SPAIN FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 44. REST OF EUROPE FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 45. REST OF EUROPE FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 46. REST OF EUROPE FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 47. ASIA-PACIFIC FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 48. ASIA-PACIFIC FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 49. ASIA-PACIFIC FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 50. ASIA-PACIFIC FINASTERIDE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 51. JAPAN FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 52. JAPAN FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 53. JAPAN FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 54. CHINA FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 55. CHINA FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 56. CHINA FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 57. AUSTRALIA FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 58. AUSTRALIA FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 59. AUSTRALIA FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 60. INDIA FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 61. INDIA FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 62. INDIA FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 63. SOUTH KOREA FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 64. SOUTH KOREA FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 65. SOUTH KOREA FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 66. REST OF ASIA-PACIFIC FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 67. REST OF ASIA-PACIFIC FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 68. REST OF ASIA-PACIFIC FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 69. LAMEA FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 70. LAMEA FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 71. LAMEA FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 72. LAMEA FINASTERIDE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 73. BRAZIL FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 74. BRAZIL FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 75. BRAZIL FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 76. SAUDI ARABIA FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 77. SAUDI ARABIA FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 78. SAUDI ARABIA FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 79. SOUTH AFRICA FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 80. SOUTH AFRICA FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 81. SOUTH AFRICA FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 82. REST OF LAMEA FINASTERIDE MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 83. REST OF LAMEA FINASTERIDE MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 84. REST OF LAMEA FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 85. ALKEM LABORATORIES LTD: KEY EXECUTIVES
- TABLE 86. ALKEM LABORATORIES LTD: COMPANY SNAPSHOT
- TABLE 87. ALKEM LABORATORIES LTD: PRODUCT SEGMENTS
- TABLE 88. ALKEM LABORATORIES LTD: PRODUCT PORTFOLIO
- TABLE 89. DR. REDDY’S LABORATORIES LTD.: KEY EXECUTIVES
- TABLE 90. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
- TABLE 91. DR. REDDY’S LABORATORIES LTD.: PRODUCT SEGMENTS
- TABLE 92. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
- TABLE 93. HETERO LABS LIMITED: KEY EXECUTIVES
- TABLE 94. HETERO LABS LIMITED: COMPANY SNAPSHOT
- TABLE 95. HETERO LABS LIMITED: PRODUCT SEGMENTS
- TABLE 96. HETERO LABS LIMITED: PRODUCT PORTFOLIO
- TABLE 97. INTAS PHARMACEUTICALS LTD.: KEY EXECUTIVES
- TABLE 98. INTAS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
- TABLE 99. INTAS PHARMACEUTICALS LTD.: PRODUCT SEGMENTS
- TABLE 100. INTAS PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
- TABLE 101. MERCK & CO., INC.: KEY EXECUTIVES
- TABLE 102. MERCK & CO., INC.: COMPANY SNAPSHOT
- TABLE 103. MERCK & CO., INC.: PRODUCT SEGMENTS
- TABLE 104. MERCK & CO., INC.: PRODUCT PORTFOLIO
- TABLE 105. ORGANON & CO.: KEY EXECUTIVES
- TABLE 106. ORGANON & CO.: COMPANY SNAPSHOT
- TABLE 107. ORGANON & CO.: PRODUCT SEGMENTS
- TABLE 108. ORGANON & CO.: PRODUCT PORTFOLIO
- TABLE 109. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 110. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 111. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
- TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 113. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 114. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 115. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
- TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 117. CIPLA LTD: KEY EXECUTIVES
- TABLE 118. CIPLA LTD: COMPANY SNAPSHOT
- TABLE 119. CIPLA LTD: PRODUCT SEGMENTS
- TABLE 120. CIPLA LTD: PRODUCT PORTFOLIO
- TABLE 121. AUROBINDO PHARMA: KEY EXECUTIVES
- TABLE 122. AUROBINDO PHARMA: COMPANY SNAPSHOT
- TABLE 123. AUROBINDO PHARMA: PRODUCT SEGMENTS
- TABLE 124. AUROBINDO PHARMA: PRODUCT PORTFOLIO
- LIST OF FIGURES
- FIGURE 01. FINASTERIDE MARKET, 2021-2031
- FIGURE 02. SEGMENTATION OF FINASTERIDE MARKET, 2021-2031
- FIGURE 03. TOP INVESTMENT POCKETS IN FINASTERIDE MARKET (2022-2031)
- FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
- FIGURE 05. LOW BARGAINING POWER OF BUYERS
- FIGURE 06. LOW THREAT OF SUBSTITUTES
- FIGURE 07. LOW THREAT OF NEW ENTRANTS
- FIGURE 08. LOW INTENSITY OF RIVALRY
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALFINASTERIDE MARKET
- FIGURE 10. FINASTERIDE MARKET, BY APPLICATION, 2021(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF FINASTERIDE MARKET FOR BENIGN PROSTATIC HYPERPLASIA (BPH), BY COUNTRY 2021 AND 2031(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF FINASTERIDE MARKET FOR MALE PATTERN BALDNESS, BY COUNTRY 2021 AND 2031(%)
- FIGURE 13. FINASTERIDE MARKET, BY TYPE, 2021(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF FINASTERIDE MARKET FOR BRANDED , BY COUNTRY 2021 AND 2031(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF FINASTERIDE MARKET FOR GENERIC, BY COUNTRY 2021 AND 2031(%)
- FIGURE 16. FINASTERIDE MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF FINASTERIDE MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF FINASTERIDE MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021 AND 2031(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF FINASTERIDE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
- FIGURE 20. FINASTERIDE MARKET BY REGION, 2021
- FIGURE 21. U.S. FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 22. CANADA FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 23. MEXICO FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 24. GERMANY FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 25. FRANCE FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 26. UK FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 27. ITALY FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 28. SPAIN FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 29. REST OF EUROPE FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 30. JAPAN FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 31. CHINA FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 32. AUSTRALIA FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 33. INDIA FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 34. SOUTH KOREA FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 35. REST OF ASIA-PACIFIC FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 36. BRAZIL FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 37. SAUDI ARABIA FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 38. SOUTH AFRICA FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 39. REST OF LAMEA FINASTERIDE MARKET, 2021-2031 ($MILLION)
- FIGURE 40. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 43. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 44. COMPETITIVE DASHBOARD
- FIGURE 45. COMPETITIVE HEATMAP: FINASTERIDE MARKET
- FIGURE 46. TOP PLAYER POSITIONING, 2021
- FIGURE 47. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 48. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 49. DR. REDDY’S LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 50. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 51. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 52. MERCK & CO., INC.: NET SALES, 2020-2022 ($MILLION)
- FIGURE 53. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 54. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 55. ORGANON & CO.: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 56. ORGANON & CO.: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 57. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 58. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 59. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 60. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 61. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)
- FIGURE 62. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 63. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 64. AUROBINDO PHARMA: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 65. AUROBINDO PHARMA: REVENUE SHARE BY REGION, 2021 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook